A detailed history of Fmr LLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Fmr LLC holds 8,754 shares of AUPH stock, worth $61,978. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,754
Previous 6,882 27.2%
Holding current value
$61,978
Previous $34,000 44.12%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.81 - $5.78 $9,004 - $10,820
1,872 Added 27.2%
8,754 $49,000
Q1 2024

May 13, 2024

SELL
$4.93 - $9.31 $4,875 - $9,207
-989 Reduced 12.57%
6,882 $34,000
Q4 2023

Feb 13, 2024

SELL
$7.13 - $9.49 $6,452 - $8,588
-905 Reduced 10.31%
7,871 $70,000
Q3 2023

Nov 13, 2023

SELL
$7.77 - $12.27 $112,276 - $177,301
-14,450 Reduced 62.21%
8,776 $68,000
Q2 2023

Aug 11, 2023

BUY
$8.96 - $11.69 $129,561 - $169,037
14,460 Added 164.96%
23,226 $224,000
Q1 2023

May 11, 2023

BUY
$5.94 - $11.27 $21,538 - $40,865
3,626 Added 70.54%
8,766 $96,000
Q4 2022

Feb 13, 2023

SELL
$4.11 - $8.14 $20.5 Million - $40.6 Million
-4,989,565 Reduced 99.9%
5,140 $22,000
Q3 2022

Nov 10, 2022

BUY
$6.66 - $12.39 $701,844 - $1.31 Million
105,382 Added 2.16%
4,994,705 $37.6 Million
Q2 2022

Aug 12, 2022

SELL
$8.95 - $12.8 $14 Million - $20 Million
-1,564,431 Reduced 24.24%
4,889,323 $49.1 Million
Q1 2022

May 13, 2022

BUY
$10.05 - $22.48 $7.29 Million - $16.3 Million
725,638 Added 12.67%
6,453,754 $79.9 Million
Q4 2021

Feb 14, 2022

SELL
$17.78 - $33.08 $64.1 Million - $119 Million
-3,607,946 Reduced 38.65%
5,728,116 $131 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $8.89 Million - $19.1 Million
813,055 Added 9.54%
9,336,062 $207 Million
Q2 2021

Aug 13, 2021

BUY
$10.0 - $14.52 $85.2 Million - $124 Million
8,523,007 New
8,523,007 $110 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.